Risk factors

Xilio is entirely dependent on its clinical-stage pipeline candidates, primarily vilastobart and XTX301, with no commercial products or revenue.

Zenas BioPharma faces significant risks typical of clinical-stage biotechs without approved products or revenue.

The July 19 Incident is the most prominent current risk, affecting customer trust, remediation costs, sales, reputation and financial results.

ProFrac faces heavy concentration and liquidity risks, alongside substantial debt of $1,138.9 million maturing in 2025. Vertical integration and acquisitions drive rapid growth but strain operational resources and create intercompany dependencies.

Florida property insurance concentration and catastrophe exposure heavily dominate the risk profile. Exclusive dependence on AmRisc as managing general agent is a core operational vulnerability. Heavy reliance on reinsurance markets directly impacts underwriting capacity and financial results.

Aligos Therapeutics faces high commercial risks centered on early-stage clinical development of treatments for CHB, MASH, and COVID-19. The company relies heavily on additional financing, faces intense biopharmaceutical competition, and has never generated product sales revenue.

The company relies heavily on residential mortgage banking, which generated 81.2% of noninterest income in 2024. Blue Ridge Bank faces intense regulatory scrutiny, specifically under the OCC Consent Order issued January 24, 2024. A significant commercial real estate concentration, totaling $847.8 million or 40.2% of total loans, increases credit risk.

This is Civista Bancshares' initial risk filing, with a primary focus on economic, credit, cybersecurity, and regulatory risks.

Caribou Biosciences faces continuous operating losses with an accumulated deficit of $448.4 million at year-end 2024. The clinical-stage company relies heavily on the success of its novel CRISPR chRDNA genome-editing technologies and allogeneic CAR-T cell therapies. Operations depend on complex manufacturing processes, third-party contractors, and the ability to secure substantial additional financing.

DarioHealth relies heavily on cash reserves, ongoing debt or equity financing, and a single major customer representing 41.6% of receivables. The company faces extensive regulatory, clinical, and privacy compliance requirements across international markets for its digital health platform.

Design Therapeutics faces heavy reliance on its novel GeneTAC platform, unproven clinical candidates like DT-216, and ongoing capital needs.

Energy sector volatility and oil price fluctuations heavily impact customer demand and financial covenant compliance. Supply chain reliance, manufacturer direct sales, and distribution authorization cancellations pose major operational threats. Growth strategies depend heavily on acquisitions, debt access, and internal expansion execution.